TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30606188

Group type: EXPERIMENTAL
Intervention: Opioid substitution treatment (OST)
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Benzodiazepine use
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Physical and mental health symptom severity, psychiatric diagnosis, and psychopharmacological medication
Number of subjects: 2176

Group type: COMPARATOR
Intervention: General population norms
Number of subjects: 2176
Study: 30606204

Group type: EXPERIMENTAL
Intervention: Letrozole associated controlled ovarian hyperstimulation (Let-COH)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Letrozole associated controlled ovarian hyperstimulation (Let-COH) with GnRHa trigger
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional controlled ovarian hyperstimulation (COH)
Number of subjects: 23
Study: 30606236

Group type: EXPERIMENTAL
Intervention: Bowel preparation by oral administering
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bowel preparation through mid-gut transendoscopic enteral tubing (TET)
Number of subjects: 96
Study: 30607254

Group type: EXPERIMENTAL
Intervention: New spatial design in psychiatric inpatient care
Number of subjects: 0
Study: 30607261

Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10-m walking test (10MWT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Berg Balance scale (BBS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence scales (ABC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Freezing of Gait Questionnaire (FOGQ)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Questionnaire-39 (PDQ-39)
Number of subjects: 42
Study: 30607301

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin aerosol, median 2 interventions per patient (range 1-6).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PIPAC procedures (2 or more).
Number of subjects: 24
Study: 30607464

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 17
Study: 30607466

Group type: EXPERIMENTAL
Intervention: Breastfeeding mothers
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control women (bottle-feeding)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 33
Study: 30607629

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily with trastuzumab 2 mg/kg and paclitaxel 80 mg/m²
Number of subjects: 29
Study: 30607646

Group type: EXPERIMENTAL
Intervention: Radionuclide imaging
Number of subjects: 34
Study: 30607798

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 321
Study: 30607806

Group type: EXPERIMENTAL
Intervention: Capstesia smartphone application for monitoring pulse pressure variation (PPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncalibrated pulse wave analysis monitor for monitoring stroke volume variation (SVV)
Number of subjects: 0
Study: 30607889

Group type: EXPERIMENTAL
Intervention: Milrinone continuous infusions
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Milrinone pharmacokinetic model
Number of subjects: 92
Study: 30608571

Group type: EXPERIMENTAL
Intervention: Biological prosthesis
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis
Number of subjects: 1443
Study: 30608597

Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids (SFAs) intake in women
Number of subjects: 14383

Group type: EXPERIMENTAL
Intervention: Even-chain SFAs intake in women
Number of subjects: 14383

Group type: EXPERIMENTAL
Intervention: Odd-chain SFAs intake in men
Number of subjects: 14383

Group type: EXPERIMENTAL
Intervention: Odd-chain SFAs intake in women
Number of subjects: 14383

Group type: EXPERIMENTAL
Intervention: Medium-chain SFAs intake in men
Number of subjects: 14383

Group type: EXPERIMENTAL
Intervention: Replacing 1% of energy from unsaturated fatty acids with even-chain SFAs in men
Number of subjects: 14383
Study: 30609007

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 30609276

Group type: EXPERIMENTAL
Intervention: Needle tenotomy with or without PRP
Number of subjects: 74
Study: 30610196

Group type: EXPERIMENTAL
Intervention: Carfilzomib 36 mg/m² combined with panobinostat
Number of subjects: 32
Study: 30610355

Group type: EXPERIMENTAL
Intervention: Postoperative radio(chemo)therapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Location of the primary tumor in the oropharynx
Number of subjects: 99
Study: 30610518

Group type: EXPERIMENTAL
Intervention: Synchronized mandibular movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30610872

Group type: EXPERIMENTAL
Intervention: Neurotropic drugs (including opioids, sedatives, hypnotics, antidepressants)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Stroke severity (high NIH Stroke Scale-score)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 504

Group type: COMPARATOR
Intervention: Neurotropic drugs or cardiovascular drugs
Number of subjects: 504
Study: 30611192

Group type: EXPERIMENTAL
Intervention: Subclinical tuberculosis treatment
Number of subjects: 654

Group type: COMPARATOR
Intervention: Active tuberculosis treatment
Number of subjects: 654
Study: 30611197

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (desflurane + remifentanil)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA, propofol + remifentanil)
Number of subjects: 40
Study: 30611255

Group type: EXPERIMENTAL
Intervention: Clinical gingivitis
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Bleeding on probing (BOP)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Probing depth (PD)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Gingival recession
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Maternal stature
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Cost barrier to dental care
Number of subjects: 1452
Study: 30611293

Group type: EXPERIMENTAL
Intervention: 2-HOBA acetate (up to 825 mg)
Number of subjects: 18
Study: 30611582

Group type: EXPERIMENTAL
Intervention: ENROUTE transcarotid neuroprotection system (NPS) during transcarotid artery revascularization (TCAR)
Number of subjects: 165
Study: 30611659

Group type: EXPERIMENTAL
Intervention: 17-gene Oncotype DX Genomic Prostate Score (GPS) assay
Number of subjects: 1200
Study: 30611839

Group type: EXPERIMENTAL
Intervention: Brachytherapy delivering 22.5 Gy in 3 fractions of 7.5 Gy
Number of subjects: 200
Study: 30612558

Group type: EXPERIMENTAL
Intervention: Radium-223, 55 kBq/kg intravenously, every 4 weeks for up to 6 cycles
Number of subjects: 708
Study: 30612568

Group type: EXPERIMENTAL
Intervention: Standard oxaliplatin-based or irinotecan-based chemotherapy
Number of subjects: 264
Study: 30612602

Group type: EXPERIMENTAL
Intervention: Long visit tests including walking test, blood tests, determination of diffusion, pulse oximetry, bioimpedance, and low radiation CT for participants with COPD.
Number of subjects: 3581

Group type: EXPERIMENTAL
Intervention: New imaging data, biomarkers, and information on new exposures such as electronic cigarettes and environmental pollution.
Number of subjects: 3581

Group type: EXPERIMENTAL
Intervention: Spirometric results and other factors associated with COPD.
Number of subjects: 3581
Study: 30612710

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, intravenous, once every 3 weeks)
Number of subjects: 92
Study: 30612825

Group type: EXPERIMENTAL
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)
Number of subjects: 13
Study: 30612959

Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as monotherapy in 13 bleeding sites (25%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as combination therapy in 22 bleeding sites (42.3%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as rescue therapy in 17 bleeding sites (32.7%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray)
Number of subjects: 50
Study: 30613413

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 464
Study: 30613427

Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30613416

Group type: EXPERIMENTAL
Intervention: Significant primary mitral regurgitation (MR)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Estimation of EDPVR
Number of subjects: 46
Study: 30614187

Group type: EXPERIMENTAL
Intervention: Circulating total testosterone (TT) > 14.76 nmol/L
Number of subjects: 248

Group type: COMPARATOR
Intervention: Circulating total testosterone (TT) ≤ 14.76 nmol/L
Number of subjects: 248
Study: 30614320

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2000

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 2000
Study: 30614531

Group type: EXPERIMENTAL
Intervention: Panitumumab plus 5-fluorouracil/leucovorin (5-FU/LV) maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU/LV ± bevacizumab maintenance
Number of subjects: 0
Study: 30614939

Group type: EXPERIMENTAL
Intervention: Budesonide therapy (1 mg BID for 8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: N/A (Control group: GERD patients)
Number of subjects: 17
Study: 30615047

Group type: EXPERIMENTAL
Intervention: Physiologic measures of sympathetic tone (resting heart rate, blood pressure, resting heart rate variability, postexercise heart rate recovery and blood pressure)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Osteopathic measures of sympathetic tone (Chapman points and viscerosomatic reflexes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Osteopathic structural examination
Number of subjects: 24
Study: 30615169

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Client-centered care coordination (C4)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Baseline STI diagnosis
Number of subjects: 226
Study: 30615302

Group type: EXPERIMENTAL
Intervention: Mildly elevated mean PAP (21-24 mm Hg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Normal mean PAP (≤20 mm Hg)
Number of subjects: 112
Study: 30615623

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of EBUS-TBNA
Number of subjects: 163
Study: 30616360

Group type: EXPERIMENTAL
Intervention: RV-pulmonary arterial coupling (Ees/Ea)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: End-systolic volume
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: End-diastolic volume/body surface area (BSA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: RV ejection fraction (EF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: End-diastolic elastance (Eed)
Number of subjects: 42
Study: 30616578

Group type: EXPERIMENTAL
Intervention: Smoke-free Teens Programme (2-day-1-night training camp, creative activities, award presentation ceremony)
Number of subjects: 856
Study: 30616617

Group type: EXPERIMENTAL
Intervention: Standard care for drug sensitive and multidrug-resistant pulmonary TB
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Standardized quality of life questionnaire and adapted WHO's generic patient cost instrument
Number of subjects: 1600
Study: 30616705

Group type: EXPERIMENTAL
Intervention: High early-childhood BI
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low early-childhood BI
Number of subjects: 87
Study: 30616737

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 4755

Group type: COMPARATOR
Intervention: Influenza-positive patients
Number of subjects: 4755

Group type: COMPARATOR
Intervention: Risk factors for mortality in influenza-positive patients
Number of subjects: 4755
Study: 30616998

Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg/day) plus Quercetin (1250 mg/day), three-days/week over three-weeks
Number of subjects: 14
Study: 30617104

Group type: EXPERIMENTAL
Intervention: Smartphone-based automated detection of nocturnal cough and sleep quality assessment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Asthma Control Test
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 94
Study: 30617198

Group type: EXPERIMENTAL
Intervention: Luspatercept (0.6-1.25 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Luspatercept (0.8 to 1.25 mg/kg)
Number of subjects: 64
Study: 30617563

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 10
Study: 30617611

Group type: EXPERIMENTAL
Intervention: Low-flow ECCO
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined system with membrane lung (0.32 m)
Number of subjects: 20
Study: 30617997

Group type: EXPERIMENTAL
Intervention: Successful reperfusion (defined as modified Thrombolysis in Cerebral Infarction grade 2b/3)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Successful reperfusion
Number of subjects: 193

Group type: COMPARATOR
Intervention: Mechanical thrombectomy in patients with NIHSS < 8
Number of subjects: 193
Study: 30618063

Group type: EXPERIMENTAL
Intervention: Counselling using the communication tool about diet
Number of subjects: 12
Study: 30618179

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg once every 3 weeks for 2 years or until disease progression/unacceptable toxicity
Number of subjects: 38
Study: 30618593

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30618764

Group type: EXPERIMENTAL
Intervention: Fixed Combination of Chinese Herbal Medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30618820

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) training and individualized nutritional support
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (details not provided)
Number of subjects: 31
Study: 30618929

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30619077

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) for gait rehabilitation, details on dosage and duration not available
Number of subjects: 0
Study: 30619080

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 51
Study: 30619351

Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA-4-Ig)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockade of OX40L
Number of subjects: 0
Study: 30619502

Group type: EXPERIMENTAL
Intervention: Diet high in cereal fiber and coffee, free of red meat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie restriction (independent of fiber, coffee, or meat)
Number of subjects: 0
Study: 30619615

Group type: EXPERIMENTAL
Intervention: Micro-particle curcumin 90 mg once daily for 6 months
Number of subjects: 500

Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 500
Study: 30620669

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 121
Study: 30621586

Group type: EXPERIMENTAL
Intervention: Group Concept Mapping (GCM)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Interviews
Number of subjects: 141
Study: 30621615

Group type: EXPERIMENTAL
Intervention: Option B+ (antiretroviral therapy throughout life)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Option A (standard of care during pregnancy and breastfeeding)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Option B+
Number of subjects: 157
Study: 30621698

Group type: EXPERIMENTAL
Intervention: neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab
Number of subjects: 0
Study: 30621699

Group type: EXPERIMENTAL
Intervention: Rapid fentanyl test strips (FTS); participants received ten FTS for personal use after training on how to use them.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rapid fentanyl test strips (FTS); participants reported giving FTS to friends at high risk for fentanyl exposure.
Number of subjects: 93
Study: 30621712

Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation with two-stage hepatectomy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 3
Study: 30621729

Group type: EXPERIMENTAL
Intervention: Nuss bar removal
Number of subjects: 9
Study: 30621829

Group type: EXPERIMENTAL
Intervention: Actigraphy metrics on POD 0 (16:00-23:00) and POD 0 night (23:00-POD 1, 06:00)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Early postoperative wrist actigraphy metrics
Number of subjects: 84
Study: 30621976

Group type: EXPERIMENTAL
Intervention: Lotus valve (Boston Scientific)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Lotus valve with Depth Guard
Number of subjects: 1014
Study: 30621982

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 222
Study: 30622089

Group type: EXPERIMENTAL
Intervention: Full-body blue light device (wavelengths: 415 nm and 450 nm)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 150
Study: 30622093

Group type: EXPERIMENTAL
Intervention: ESRA-C intervention
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control (electronic symptom assessment and participant symptom reports alone)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Participants who received clinician recommendations
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Participants who did not follow clinician recommendations
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 370
Study: 30622094

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) with Wildflowers app
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cognitive training with game 2048
Number of subjects: 86
Study: 30622180

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 5
Study: 30622321

Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Number of subjects: 5
Study: 30622463

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training for 14 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo training for 14 days
Number of subjects: 134
Study: 30622502

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30622509

Group type: EXPERIMENTAL
Intervention: Educational and reminder-based intervention for adherence to direct oral anticoagulant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 30622667

Group type: EXPERIMENTAL
Intervention: Atosiban (administered continuously for 48 hours)
Number of subjects: 56
Study: 30622716

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 270
Study: 30622728

Group type: EXPERIMENTAL
Intervention: Arts-based intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study: 30622733

Group type: EXPERIMENTAL
Intervention: Gradual reloading exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 44
Study: 30622737

Group type: EXPERIMENTAL
Intervention: Abatacept+MTX
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo+MTX
Number of subjects: 405
Study: 30622936

Group type: EXPERIMENTAL
Intervention: Krill oil supplementation during breastfeeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study: 30623229

Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP) at a dose of 112.5 mg/m²
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP) at doses 35-175 mg/m²
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP)
Number of subjects: 6
Study: 30623276

Group type: EXPERIMENTAL
Intervention: ontuxizumab 2-12 mg/kg weekly (part 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ontuxizumab 4 or 8 mg/kg weekly, or 12 mg/kg biweekly (part 2)
Number of subjects: 46
Study: 30623279

Group type: EXPERIMENTAL
Intervention: CorTempR™ Wireless Ingestible Temperature Sensor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3M Bair Hugger™ Temperature Monitoring System Zero Flux Thermometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: oesophageal probe
Number of subjects: 30
Study: 30623351

Group type: EXPERIMENTAL
Intervention: EchoPAC (GE Healthcare)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: QLAB (Philips Healthcare)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both EchoPAC and QLAB
Number of subjects: 156
Study: 30623414

Group type: EXPERIMENTAL
Intervention: Actigraphy (accelerometer worn for up to 7 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 66
Study: 30624149

Group type: EXPERIMENTAL
Intervention: Methylprednisolone group (MG, N = 18; 500 mg in the CPB priming)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-methylprednisolone group (NMG, N = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methylprednisolone group (MG)
Number of subjects: 36
Study: 30624546

Group type: EXPERIMENTAL
Intervention: Larotrectinib (100 mg twice daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 70
Study: 30624587

Group type: EXPERIMENTAL
Intervention: LA-enriched diet (FADSDIET) for 4 weeks
Number of subjects: 62
Study: 30624603

Group type: EXPERIMENTAL
Intervention: 5 g fish oil/d containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid for 6 weeks
Number of subjects: 208